James Lynch

James is a molecular biologist with a Biochemistry degree and PhD from the University of Manchester. He then undertook post-doctoral studies at the CRUK Manchester Institute studying the role of epigenetic regulators in acute myeloid leukaemia. He joined AstraZeneca as a senior scientist in the Oncology IMED Biotech unit in 2014 and has expertise in target identification/validation and leadership of early stage discovery programmes